Not exact matches
Advancing Escalier's drug candidates through human proof - of - concept studies NIJMEGEN, The Netherlands and ENCINITAS,
California, — Escalier Biosciences BV, a privately held
biopharmaceutical company, today announced the closing of a $ 19 million Series B financing.
When a scientist posts a publication, users who are linked to the paper or cited in it receive notifications, a function biotechnologist Douglas Jolly, from Tocagen, a
biopharmaceutical company in San Diego,
California, uses «to track who is citing me and my collaborators.»
VXGN is a
biopharmaceutical company based in South San Francisco,
California.